Solid Biosciences Inc. Shareholders' Equity
Solid Biosciences Inc. (SLDB) had Shareholders' Equity of $374.07 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $374.07M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $374.13M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $180.01M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $217.95M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $374.07M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $374.13M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $180.01M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $217.95M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $258.29M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $294.46M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $137.25M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $167.02M 10-Q · filed 2025-11-03 |
| 2024-06-30 | $193.25M 10-Q · filed 2025-11-03 |
| 2024-03-31 | $210.72M 10-Q · filed 2025-11-03 |
| 2023-12-31 | $126.48M 10-K · filed 2026-03-19 |
| 2023-09-30 | $144.36M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $163.73M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $183.79M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $211.67M 10-K · filed 2025-03-06 |
| 2022-09-30 | $143.28M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $162.24M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $185.51M 10-Q · filed 2023-08-14 |
| 2021-12-31 | $208.21M 10-Q · filed 2023-11-08 |
| 2021-09-30 | $223.36M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $237.94M 10-Q · filed 2022-11-10 |
| 2021-03-31 | $253.00M 10-Q · filed 2022-08-11 |
| 2020-12-31 | $132.09M 10-Q · filed 2022-11-10 |
| 2020-09-30 | $22.23M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $40.71M 10-Q · filed 2021-11-03 |
| 2020-03-31 | $56.46M 10-Q · filed 2021-08-16 |
| 2019-12-31 | $80.05M 10-Q · filed 2021-11-03 |
| 2019-09-30 | $108.53M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $76.50M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $99.11M 10-Q · filed 2020-08-06 |
| 2018-12-31 | $125.18M 10-Q · filed 2020-11-05 |
| 2018-09-30 | $145.07M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $162.29M 10-Q · filed 2019-11-12 |
| 2018-03-31 | $178.95M 10-Q · filed 2019-08-14 |
| 2017-12-31 | -$59.26M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |